Mahesh Karande (Omega)

'Ex­quis­ite con­trol': Flag­ship pulls off $85M ral­ly around Omega Ther­a­peu­tic­s' clin­i­cal push for epi­ge­net­ic pro­gram­ming tech

Omega Ther­a­peu­tics be­gan, as all biotech fledg­lings in­cu­bat­ed at Flag­ship Labs do, with an off-the-wall ques­tion: Can one con­trol gene ex­pres­sion but not cre­ate the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.